A new SLAS Discovery article available now for free ahead-of-print, offers perspective from researchers at Coyne Scientific (Atlanta, GA) about Clinical Trials in a Dish (CTiD), a novel strategy that bridges preclinical testing and clinical trials.
The pharmaceutical industry is facing unprecedented challenges as the cost of developing new drugs reaches unsustainable levels, fueled in large part by high attrition rates in clinical development. This new CTiD platform allows pharmaceutical companies to test, at the population level, novel drugs on patient cells before moving into actual clinical trials. Because current preclinical strategies don't follow this principle, CTiD offers the potential to significantly impact drug discovery and development.
Recent demonstrations show various human induced pluripotent stem cell-derived (hiPSCs) cell types (cardiac, neuronal, hepatic) recapitulate a specific individual's drug response (rather than that of a generic human being) and have opened up new avenues that support the concept of screening for cell-based safety and toxicity at the level of a population. The concept of CTiD is to satisfy, in an in vitro setting, the defining biological truth that establishes the need for a multi-patient clinical trial, which is that drug responses vary by human. CTiD studies are efficient, allow the study of a range of clinical doses, and can be executed at a fraction of the cost outside of the rigid and heavily regulated clinical testing environment.
CTiD studies are poised to revolutionize thinking about practical, immediate and near-term applications in the field of drug discovery and development. CTiD can lead to insights that cannot be obtained so early and economically in drug development by any other approach. Although still requiring improvements and enhancements, CTiD offers to refine the selection of drugs to move into clinical development, leading to reduced attrition and enabling safe drugs that address unmet medical needs to reach patients more quickly.
Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development can be accessed for free at http://journals.sagepub.com/doi/full/10.1177/2472555218775028. For more information about SLAS and its journals, visit http://www.slas.org/journals.
A PDF of this article is available to credentialed media outlets upon request. Contact firstname.lastname@example.org.
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).
SLAS DISCOVERY Advancing the Science of Drug Discovery